Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $19.63.

Several equities research analysts recently commented on STOK shares. Needham & Company LLC boosted their price objective on shares of Stoke Therapeutics from $14.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. increased their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a report on Tuesday, March 26th. Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. Finally, TD Cowen raised Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th.

Insider Buying and Selling

In other news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $4.80, for a total value of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares of the company’s stock, valued at approximately $33,508.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at approximately $126,550.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now directly owns 6,981 shares in the company, valued at approximately $33,508.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,741 shares of company stock worth $223,115. Insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Lynx1 Capital Management LP bought a new stake in shares of Stoke Therapeutics in the 3rd quarter worth approximately $6,738,000. Goldman Sachs Group Inc. grew its stake in shares of Stoke Therapeutics by 976.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,391,431 shares of the company’s stock valued at $7,319,000 after buying an additional 1,262,126 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Stoke Therapeutics in the 1st quarter valued at approximately $25,011,000. Millennium Management LLC increased its stake in shares of Stoke Therapeutics by 121.9% in the second quarter. Millennium Management LLC now owns 949,658 shares of the company’s stock worth $12,545,000 after purchasing an additional 521,661 shares during the period. Finally, BlackRock Inc. grew its stake in shares of Stoke Therapeutics by 24.3% in the second quarter. BlackRock Inc. now owns 2,293,670 shares of the company’s stock worth $24,382,000 after acquiring an additional 448,175 shares during the last quarter.

Stoke Therapeutics Stock Up 3.3 %

Shares of STOK opened at $12.57 on Friday. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.40. The company has a 50-day simple moving average of $7.21 and a 200-day simple moving average of $5.40. The company has a market capitalization of $581.99 million, a PE ratio of -5.30 and a beta of 0.77.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.